About EnteraSense
EnteraSense is a company based in Galway (Ireland) founded in 2016. EnteraSense has raised $1.14 million across 3 funding rounds from investors including European Commission and European Union. EnteraSense operates in a competitive market with competitors including Prometheus Laboratories, Viome Life Sciences, NinePoint Medical, InDex Pharmaceuticals and Given Imaging, among others.
- Headquarter Galway, Ireland
- SectorsHealthcare
- Website enterasense.com
- Social X
- Total Equity Funding$1.14M (USD)
in 3 rounds
- Latest Funding Round$2.85M (USD), Grant
Jan 2019
- InvestorsEuropean Commission
& 1 more
Funding Insights of EnteraSense
EnteraSense has successfully raised a total of $1.14M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $2.85 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.14M
- Total Rounds 3
- Last Round Grant — $2.85M
- First Round $1.18M
(Jan 2019)
- Investors Count 2
All 3 funding rounds of EnteraSense with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | $1.14M | Seed | – | – | – |
| Jan 2019 | $2.85M | Grant | – | – | |
| Jan 2019 | $1.18M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in EnteraSense
EnteraSense has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Commission and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for EnteraSense
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of EnteraSense
3 dated milestones of EnteraSense across 3 years, from founding to its latest funding, stage changes and deals.
- Founded EnteraSense is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $2.8M.
Competitors of EnteraSense
EnteraSense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prometheus Laboratories, Viome Life Sciences, NinePoint Medical, InDex Pharmaceuticals and Given Imaging, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prometheuslabs.com | 1995 | San Diego, United States | – | 474 | Diagnostics and therapeutics for gastrointestinal and personalized medicine are developed. | |
| viomelifesciences.com | 2016 | Bothell, United States | $92.44M | 136 | Provider of tests to prevent, treat, and cure chronic diseases, and cancer | |
| ninepointmedical.com | 2008 | Bedford, United States | $98.26M | 25 | Optical coherence tomography systems for tissue microstructure imaging are developed. | |
| indexpharma.com | 2000 | Stockholm, Sweden | $45.42M | – | DNA-based immunomodulatory drugs for ulcerative colitis are developed. | |
| givenimaging.com | 1998 | Minneapolis, United States | – | – | Capsule endoscopy systems for GI imaging | |
| gtechmedical.com | 2010 | Mountain View, United States | $6.93M | 3 | Diagnostic device company | |
| xillix.com | 2002 | Toronto, Canada | $5.5M | – | Develops real-time fluorescence imaging systems for medical applications. | |
| goodgut.eu | 2014 | Girona, Spain | $900,240 | – | Diagnosis and treatment of digestive diseases based on intestinal microbiota analysis | |
| stelladx.com | 2020 | New York, United States | – | – | Molecular diagnostics solutions for esophageal diseases are developed. |
Detailed competitors of EnteraSense
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enterasense
Complete news archive for EnteraSense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to EnteraSense
10 companies that operate in the same segment as EnteraSense (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EnteraSense
EnteraSense was founded in 2016 and raised its 1st funding round 3 years after it was founded.
EnteraSense is headquartered in Galway, Ireland.
EnteraSense is a funded company, having raised a total of $1.14M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.18M, raised on Jan 2019.
Enterasense develops ingestible biosensors for GI disease. Its flagship product Sentinel is a sensor that is embedded in a capsule which is swallowed by the patient. The sensor then wirelessly transmits data to an accompanying app for the detection of bleeds in the upper GI tract.
EnteraSense's top competitors include Viome Life Sciences, Prometheus Laboratories and NinePoint Medical.
EnteraSense has 2 investors. Key investors include European Commission, and European Union.